Exercise as it relates to Disease/Sudden cardiac death in athletes

From Wikibooks, open books for an open world
Jump to navigation Jump to search

First ever reported sudden cardiac death (SCD) in an athlete occurred as early as 490 BC, when a trained runner called Pheidippides collapsed and died after running from Marathon to Athens.[1] Recent athletes who were victims of SCD includes basketball players Hank Gathers (in 1990), Pete Maravich (in 1988) and Reggie Lewis (in 1993), marathon runner Jim Fixx (in 1984), US Olympic volleyball player Flo Hyman (in 1986), and Olympic figure skater Sergei Grinkov (in 1995).[1] There is no universally accepted definition for SCD. It is broadly defined as non traumatic and unexpected cardiac arrest that occurs within 6 hours of a previously normal state of health.[1][2] It is important to identify the athletes those who are at risk, however, unfortunately sudden death could be the first symptom in an athlete with a recognisable and potentially preventable etiology.[2]

Mechanisms[edit | edit source]

Mechanisms behind SCD is not fully understood. However, it is believed SCD in athletes is resulted by combination of factors such as increased myocardial oxygen demand, aortic rupture, shortened diastole and coronary perfusion time, alteration in sympathetic and parasympathetic tone, release of thromboxane A2 (a potent vasoconstrictor), enhanced blood coagulability, lactic acidosis, intracellular and extracellular electrolyte derangement, and increased blood temperature during intense exercise.[2][3][4]

Epidemiology[edit | edit source]

SCD is a rare condition, though true incidence is not verified.[1][5][6] Epidemiological studies show that athletic population is at 2.8 times greater risk of SCD compared to non-athletic counterpart.[4][7][8] Estimated incidence amongst athletes worldwide varies between 2 per 100000 and 1 per 300000.[1][2][4][9][10] There are 50 to 100 cases reported annually in USA.[1] Despite the low incidence SCD represents 30% of all non-traumatic deaths amongst athletes.[1] Significantly higher proportion of men have suffered from SCD compared to women and the risk increases with age.[6][7][8] About 68% of the cases were reported in basketball and soccer.[1][4][8]

Causes[edit | edit source]

SDC is predominantly caused by structural non-atherosclerotic heart diseases. It is understood that combination of high intensity exercise and underlying heart disease triggers SCD rather than by exercise alone.[1] Common causes can be categorised into structural,electrical and acquired cardiac abnormalities.[1][2][3][8][10][11][12][13][14][15]

An echocardiogram displaying systolic anterior motion of the mitral valve due to hypertrophic cardiomyopathy.
Structural cardiac abnormalities Electrical cardiac abnormalities Acquired cardiac abnormalities


Hypertrophic cardiomyopathy (36% of deaths)
Congenital coronary artery anomalies (17% to 19% of deaths)
Idiopathic left ventricular hypertrophy (9% to 10% of deaths)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Marfan syndrome
Mitral valve prolapse/ aortic stenosis


Wolff Parkinson White Syndrome
Congenital long QT syndrome
Brugada syndrome
Catecholaminergic polymorphic ventricular tachycardia


Infection (myocarditis)
Trauma (commotion cordis)
Toxicity (illicit/performance enhancing drugs)
Environment (hypo/hyperthermia)

Prevention[edit | edit source]

Several strategies have been outlined by American Health Association, European Society of Cardiology and 36th Bathesda Conference report in order to prevent SCD in athletes.

Italian protocol for preparticipation screening for cardiovascular disease in young athletes
  • Pre-participation screeninɡ[5][6][8][11][15][16]
    • Family and personal history
    • Physical examination
    • Twelve-lead electrocardiogram (ECG)

If abnormalities detected or reasonable suspicions arise, submaximal exercise stress test is recommended.[2][6] Further investigations through cardiac imagine could be carried out.[5][6][12][16][17]

Recommendations[edit | edit source]

  • Pre-participation screening should be carried out in all competitive athletes.[5][6][8][11][15][16]
  • External defibrillators and advanced cardiac life support units should be present at competitive events and training venues.[3]
  • Young athletes who present with chest pain, dizziness and syncope during or after exercise should seek medical attention.[14]
  • Young athletes diagnosed with hypertrophic cardiomyopathy should only participate in low intensity sports whether patients are symptomatic or asymptomatic.[2][8][11][16]
  • Patients diagnosed with coronary abnormalities should not participate in any competitive sports. Patients treated with surgical intervention can participate in sports after 6 months after the operation if ischemia is not present during maximal exercise testing.[2][8][11][16]
  • Patients with Arrhythmogenic right ventricular cardiomyopathy should not participate in any competitive sports.[2][8][16]
  • Athletes thought to have myocarditis should be withdrawn from sports for 6 months. Before returning to sport, thorough investigation is warranted.[2][8][11][16]
  • Participation restriction in sports for patients diagnosed with congenital heart disease is dependent on the severity of the condition and medical clearance is required.[2][8][16]
  • Participating in recreational (low to moderate intensity) activity is encouraged to maintain physical and mental health, even when participating in competitive sports is restricted.[11]

Further reading[edit | edit source]

References[edit | edit source]

  1. a b c d e f g h i j Germann C, Perron A. Sudden cardiac death in athletes: A guide for emergency physicians. American Journal of Emergency Medicine. 2005; 23: p504-509
  2. a b c d e f g h i j k Cook S, Franklin W. Evaluation of the athlete who 'goes to ground'. Progress in Pediatric Cardiology. 2001; 13: p91-100
  3. a b c Turakhia M, Tseng Z. Sudden cardiac death: Epidemiology, mechanisms, and therapy. Current Problems in Cardiology. 2007; p502-546
  4. a b c d Ferreira M, Silva P, Abreu L, et al. Sudden cardiac death athletes: A systematic review. Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology. 2010; 2(19):p2-7
  5. a b c d Faber L, Buuren F. Athlete screening for occult cardiac disease. Journal of American College of Cardiology. 2008; 51(10):p1040-1041
  6. a b c d e f Corrado D, Migliore F, Bevilacqua M. Sudden cardiac death in athletesː Can it be prevented by screening?. Hertz. 2009; 34ːp259-266
  7. a b Corrado D, Biffi A, Migliore F, Primary prevention of sudden death in young competitive athletes by preparticipation screening. Cardiac Electrophysiologic Clinic. 2013; 5ːp13-21
  8. a b c d e f g h i j k Chandra N, Bastiaenen R, Papadakis M. Sudden cardiac death in young athletesː Practical challenges and diagnostic dilemmas. Journal of American College of Cardiology. 2013; 61(10)ːp1027-1040
  9. Corrado D, Basso C, Schiavon M, et al. Preparticipation screening of young athletes for prevention of sudden cardiac death. Journal of American College of Cardiology. 2008; 52(24)ːp1981-1989
  10. a b c d e f g Cava J, et al. Exercise recommendation and risk factors for sudden cardiac death. Pediatric Clinic of North America. 2004; 51ːp1401-1420
  11. a b Arrigan M, et al. Imaging spectrum of sudden athlete cardiac death. Clinical Radiology. 2011; 66ːp203-233
  12. Thiene G, et al. Prevention of sudden cardiac death in the young and in athletesː dream or reality? Cardiovascular Pathology. 2010; 19ːp207-217
  13. a b Shirley K, Adirim T. Sudden cardiac death in young athletes. Clinical Pediatric Emergency Medicine. 2005; 6ːp194-199
  14. a b c Halabchi F, et al. Sudden cardiac death in young athletesː A literature review and special consideration in asia. Asian Journal of Sports Medicine. 2011; 2(1)ːp1-15
  15. a b c d e f g h Maron B, Zipes D. 36th Bethesda Conferenceː Eligibility recommendations for competitive athletes with cardiovascular disease. Journal of American College of Cardiology. 2005; 45(8)ːp 1312-1375
  16. Gerche A, et al. Athlete's heartː The potential of multimodality imaging to address the critical remaining questions. Cardiology Imaging. 2009; 2ːp350-363